← Back to Search

Monoclonal Antibodies

CNTY-101 for Lupus (CALiPSO-1 Trial)

Phase 1
Recruiting
Research Sponsored by Century Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have a diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus for at least 6 months.
Participants must have elevated anti- double stranded deoxyribonucleic acid (anti-dsDNA) and/or elevated anti-Smith antibody test at Screening (a single retest of previously positive participants who were negative at screening will be allowed).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug called CNTY-101 in people with autoimmune diseases like lupus. The study will determine the safety and effectiveness of different doses of the drug in patients who have

Who is the study for?
This trial is for people with tough-to-treat B cell-mediated autoimmune diseases, like severe lupus. They should have a specific diagnosis of SLE for at least 6 months and active disease as shown by certain test scores. Those with stable diabetes or hypothyroidism can join if their condition has been under control for over a month.
What is being tested?
CALiPSO-1 is testing CNTY-101's safety and effectiveness in patients with refractory autoimmune conditions. It involves giving participants CNTY-101 along with IL-2 and lymphodepleting chemotherapy to see how well it works against severe symptoms of diseases like lupus.
What are the potential side effects?
Possible side effects may include reactions related to the immune system, such as inflammation in different body parts due to IL-2, complications from lowering the body's immune cells through chemotherapy, and any specific effects tied to CNTY-101.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with SLE for at least 6 months.
Select...
I have high levels of anti-dsDNA or anti-Smith antibodies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2: Dose Expansion PhaseExperimental Treatment3 Interventions
Participants will receive treatments using the recommended phase 2 regimen (RP2R) confirmed during Part 1 of the study.
Group II: Part 1: Dose Escalation PhaseExperimental Treatment3 Interventions
Participants with SLE and LN will undergo lymphodepleting chemotherapy (LDC) followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2). After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IL-2
2007
Completed Phase 4
~1180

Find a Location

Who is running the clinical trial?

Century Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
450 Total Patients Enrolled
~20 spots leftby Aug 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top